2025-03-01 2026-03-31 2026-03-31 false 16230220 The Lymph Clinic Limited 96040Physical well-being activities iso4217:GBP xbrli:pure 162302202025-03-01 162302202026-03-31 162302202025-03-01 2026-03-31 16230220bus:SmallEntities2025-03-01 2026-03-31 16230220bus:AuditExempt-NoAccountantsReport2025-03-01 2026-03-31 16230220bus:FullAccounts2025-03-01 2026-03-31 16230220core:WithinOneYear2026-03-31 16230220core:AfterOneYear2026-03-31 16230220core:WithinOneYear2025-03-01 2026-03-31 16230220core:AfterOneYear2025-03-01 2026-03-31 16230220core:CurrentFinancialInstruments2026-03-31 16230220core:Non-currentFinancialInstruments2026-03-31 16230220core:CurrentFinancialInstruments2025-03-01 2026-03-31 16230220core:Non-currentFinancialInstruments2025-03-01 2026-03-31 16230220core:LandBuildings2025-03-01 2026-03-31 16230220core:FurnitureFittings2025-03-01 2026-03-31 16230220core:OfficeEquipment2025-03-01 2026-03-31 16230220core:Vehicles2025-03-01 2026-03-31 16230220core:PlantMachinery2025-03-01 2026-03-31 16230220core:OtherPropertyPlantEquipment2025-03-01 2026-03-31 16230220core:LandBuildings2026-03-31 16230220core:PlantMachinery2026-03-31 16230220core:Vehicles2026-03-31 16230220core:FurnitureFittings2026-03-31 16230220core:OfficeEquipment2026-03-31 16230220core:OtherPropertyPlantEquipment2026-03-31 16230220core:Right-of-useAssets2025-03-01 2026-03-31 16230220core:Right-of-useAssets2026-03-31 16230220core:Goodwill2025-03-01 2026-03-31 16230220core:PatentsTrademarksLicencesConcessionsSimilar2025-03-01 2026-03-31 16230220core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-03-01 2026-03-31 16230220core:OtherResidualIntangibleAssets2025-03-01 2026-03-31 16230220core:Goodwill2026-03-31 16230220core:DevelopmentCostsCapitalisedDevelopmentExpenditure2026-03-31 16230220core:PatentsTrademarksLicencesConcessionsSimilar2026-03-31 16230220core:OtherResidualIntangibleAssets2026-03-31 16230220dpl:CostSales2025-03-01 2026-03-31 16230220dpl:AdministrativeExpenses2025-03-01 2026-03-31 16230220dpl:DistributionCosts2025-03-01 2026-03-3116230220core:ShareCapital2026-03-31 16230220core:SharePremium2026-03-31 16230220core:RevaluationReserve2026-03-31 16230220core:OtherReservesSubtotal2026-03-31 16230220core:ShareCapitalPreferenceShares2026-03-31 16230220core:CapitalRedemptionReserve2026-03-31 16230220core:OtherCapitalReserve2026-03-31 16230220core:RetainedEarningsAccumulatedLosses2026-03-3116230220core:ShareCapital2025-03-01 2026-03-31 16230220core:SharePremium2025-03-01 2026-03-31 16230220core:RevaluationReserve2025-03-01 2026-03-31 16230220core:OtherReservesSubtotal2025-03-01 2026-03-31 16230220core:RetainedEarningsAccumulatedLosses2025-03-01 2026-03-311623022012025-03-01 2026-03-31 1623022022025-03-01 2026-03-3116230220core:ShareCapital12025-03-01 2026-03-31 16230220core:ShareCapital22025-03-01 2026-03-3116230220core:SharePremium12025-03-01 2026-03-31 16230220core:SharePremium22025-03-01 2026-03-3116230220core:RevaluationReserve12025-03-01 2026-03-31 16230220core:RevaluationReserve22025-03-01 2026-03-3116230220core:RetainedEarningsAccumulatedLosses12025-03-01 2026-03-31 16230220core:RetainedEarningsAccumulatedLosses22025-03-01 2026-03-311623022012025-03-01 2026-03-3116230220core:Non-currentFinancialInstrumentscore:CostValuation2025-03-01 16230220core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-03-31 16230220core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-03-3116230220core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-03-31 16230220core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2026-03-31 16230220core:Non-currentFinancialInstrumentscore:CostValuation2026-03-3116230220core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-03-01 16230220core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-03-31 16230220core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-03-31 16230220core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-03-31 16230220core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2026-03-31 16230220core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-03-31 16230220core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2026-03-3116230220core:Non-currentFinancialInstruments2026-03-31 16230220core:Non-currentFinancialInstruments2025-02-2816230220bus:Director12025-03-01 2026-03-3116230220bus:PrivateLimitedCompanyLtd2025-03-01 2026-03-31
The Lymph Clinic Limited
Unaudited Financial Statements
for the period ended 31 March 2026
Company registration number 16230220
(England and Wales)

Company Information

For the period 1 March 2025 to 31 March 2026
Director Kellali, Sasha

Registered office Red House Farm
Red House Lane
Altrincham
WA14 5RL

Registered number 16230220

Accountant FD Vision Ltd t/a yourFD
1728 Davenport House
261 Bolton Road
Bury
Greater Manchester
BL8 2NZ

Statement of Financial Position

As at 31 March 2026
Notes
2026
£
£
Fixed assets
Tangible assets
4
14,528
14,528
Current assets
Debtors
5,653
5,653
Creditors
Amounts falling due within one year
5
(14,385)
(14,385)
Net current assets (liabilities)
(8,732)
Total assets less current liabilities
5,796
Creditors
Amounts falling due after one year
6
6,661
6,661
Net assets (liabilities)
12,457
Capital and reserves
Called up share capital
100
Profit and loss account
12,357
Total equity
12,457

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the director on 23 September 2026 and are signed on its behalf by:

Kellali, Sasha
Kellali, Sasha
Director

Company registration number 16230220

Notes to the Financial Statements

For the period 1 March 2025 to 31 March 2026

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.


Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.


Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.3. Pensions

Defined contribution pension plan

The company operates a defined contribution pension plan for the benefit of its employees. Contributions are recognised as expenses as they become payable. Differences between contributions payable in the year and those actually paid are recognised as either prepayments or accruals in the balance sheet. The assets of the defined contribution pension scheme are held separately from those of the company in an independently administered fund.

Defined benefit pension plan

The company operates a defined benefit plan for certain employees. A defined benefit plan defines the pension benefit an employee will receive on retirement, usually dependent upon several factors including age, length of service and remuneration. A defined benefit plan is a pension plan that is not a defined contribution plan.


The liability recognised in the balance sheet in respect of the defined benefit plan is the present value of the defined benefit obligation at the reporting date less the fair value of the plan assets at the reporting date.


The defined benefit obligation is calculated using the projected unit credit method. Annually the group engages independent actuaries to calculate the obligation. The present value is determined by discounting the estimated future payments using market yields on high quality corporate bonds denominated in sterling and that have terms approximating the estimated period of the future payments ('discount rate').


The fair value of plan assets is measured in accordance with the FRS 102 fair value hierarchy and in line with the group's policy for similarly held assets. This includes the use of appropriate valuation techniques. Actuarial gains and losses from experience adjustments and changes in assumptions are charged or credited to other comprehensive income. These amounts together with the return on plan assets, less amounts included in net interest, are disclosed as 'remeasurement of net defined benefit liability'.


The cost of the defined benefit plan, recognised in profit or loss as employee costs, except where included in the cost of an asset, comprises: the increase in pension benefit liability from employee service during the period; and the cost of plan introductions, benefit changes, curtailments and settlements.

2.4. Tangible fixed assets and depreciation

All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

2.5. Trade and other debtors

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

2.6. Related parties

A related party is a person or entity that is related to the company. This includes individuals with control or significant influence, members of key management personnel, and entities within the same group. All transactions with related parties are disclosed in the notes to the financial statements. Disclosure includes the nature of the related party relationship, the amount of the transactions, and any outstanding balances and commitments at the reporting date. As permitted by FRS 102, disclosure is not required of transactions entered into between two or more members of a group, provided that any subsidiary which is a party to the transaction is wholly owned by such a member.

3. Employees

The average number of employees during the year was 7.

4. Tangible fixed assets

Plant and machinery
Office equipment
Total
£
£
£
Cost
Additions
15,497
1,594
17,091
At 31 March 2026
15,497
1,594
17,091
Depreciation and impairment
Charge for the period
2,324
239
2,563
At 31 March 2026
2,324
239
2,563
Net book value
At 31 March 2026
13,173
1,355
14,528

5. Creditors due within one year

2026
£
Other creditors
14,385
Total
14,385

6. Creditors due after one year

2026
£
Directors loan account
(6,661)
Total
(6,661)